<p>Katy Beckermann discusses the TiNivo-2 study presented at ESMO 2024.</p>

Episode 344: ESMO 2024 - NKT2152, a HIF inhibitor in RCC

Broadcasting the latest developments in GU cancer

Hosted by Brian Rini and Tom Powles 

Brian Rini MD is an Ingram Professor of Medicine (Hematology/Oncology), Vanderbilt-Ingram Cancer Center
Tom Powles is the Director of Barts Cancer Centre, St Bartholomew's Hospital and Professor of Genitourinary Oncology, Queen Mary University of London